Triple drug cocktail targets tough stomach cancer
NCT ID NCT04209686
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study is testing a combination of three drugs—paclitaxel (a chemotherapy), pembrolizumab (an immunotherapy), and olaparib (a targeted therapy)—in 36 adults with advanced gastric or gastroesophageal cancer that has worsened after one prior treatment. The goal is to see if the triple therapy is safe and can improve overall survival. Participants receive the drugs intravenously and by mouth over 21-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paclitaxel, pembrolizumab, and olaparib
What this could lead to
If successful, this combination could offer a new treatment option for advanced gastric cancer patients who have run out of standard therapies.
What could go wrong
This is a small, early-phase trial with only 36 participants, so results may not apply broadly. The three-drug combination may cause significant side effects, and it is not yet known if it improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States